About T3 MGen
T3 MGen is a company based in Bengaluru (India) founded in 2021 by Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, and Nameirakpam Bunindro Singh. It operates as a B2B and Research Collaboration. The company has 1 employees as of March 31, 2022. T3 MGen offers products and services including Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators. T3 MGen operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Aclaris Therapeutics, Chimerix and Escient Pharmaceuticals, among others.
- Headquarter Bengaluru, India
- Employees 1 as on 31 Mar, 2022
- Founders Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, Nameirakpam Bunindro Singh
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name T-3 Molecular Genetics (T-3 Mgen) Private Limited
- Date of Incorporation 20 Jul, 2021
- Jurisdiction Bangakore, Karnataka, India
-
Annual Revenue
$908.64 (USD)0as on Mar 31, 2022
-
Net Profit
-$2.92 K (USD)0as on Mar 31, 2022
-
EBITDA
-$2.55 K (USD)0as on Mar 31, 2022
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1
as on Mar 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of T3 MGen
T3 MGen offers a comprehensive portfolio of products and services, including Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators.
Identifies and engineers biopeptides for clinical uses with AI and ML tools.
Targets early diagnosis of ulcerative colitis and Crohn's disease through research.
Screens natural compounds to modulate T regulatory cells for disease treatment.
Funding Insights of T3 MGen
Detailed funding history for T3 MGen
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by T3 MGen
Investment portfolio details for T3 MGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - T3 MGen
Detailed financials for T3 MGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
T3 Mgen Comparisons
Peer comparison for T3 MGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of T3 MGen
T3 MGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Aclaris Therapeutics, Chimerix and Escient Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
Detailed competitors of T3 MGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on T3 Mgen
Complete news archive for T3 MGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about T3 MGen
T3 MGen was founded in 2021.
T3 MGen is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Narendra Dnyanoba Dhele is the current CEO of T3 MGen. They have also founded this company.
As of Mar 31, 2022, the latest employee count at T3 MGen is 1.
Annual revenue of T3 MGen is $908.64 as on Mar 31, 2022.
T3 Molecular Genetics is a seed-stage biotechnology company based in Bengaluru, India, focusing on solving unmet challenges in life sciences. Their multidisciplinary team of molecular biologists, data scientists, and immunologists innovates immune cell modulation technologies. They use AI, ML, and cutting-edge tools for peptide engineering, biomarker discovery, and small molecule screening to develop therapeutics for inflammatory and infectious diseases. Collaborations with institutions drive their research activities.
T3 MGen's top competitors include Moderna, Juno Therapeutics and Adaptive Biotechnologies.
T3 MGen offers Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators.